Drug-Drug Interactions in Patients From an Internal Medicine Service

Ibáñez, Ana Belén Pereira; Castell, María Victoria; García, J C; E, Puche

doi:10.1016/s2173-5085(08)70051-0

Cited by 6 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The uncontrolled use of PPIs is associated with atrophic gastritis, interstitial nephritis, induction of ulcer symptoms, thrombocytopenia, osteoporosis and endocrine disorders such as gynecomastia and impotence [9][10][11][12] . The probability of adverse reactions to PPIs also increases with polymedication and is higher in patients with chronic diseases 13,14 . This is due in part to the metabolism of PPIs through cytochrome P450, which leads to various drugs interactions by extending their half-life and thereby causes harmful systemic effects 14 .…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, it will be necessary to provide continuing education to physicians in order to ensure that they are up to date in their management of ulcers, especially with the use of PPIs. Such physicians must be trained to prescribe the appropriate medications in the appropriate doses, and educated about the conditions and comorbidities for which PPI use is indicated or contraindicated [7][8][9][10][11][12][13][14][15][16][17] .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prescribing patterns and economic costs of proton pump inhibitors in Colombia

et al. 2013

View full text Add to dashboard Cite

Objective: To determine the prescribing patterns for proton pump inhibitors and to estimate the economic cost of their use in a group of patients affiliated with the Colombian Health System. Methods: This is a descriptive observational study. Data for analysis consisted of prescriptions dispensed between October 1st, 2010 and October 31st, 2010 and were collected from a systematic database of 4.2 million members. Socio-demographic variables were considered along with the defined daily dose, co-medication, convenience of the indication for proton pump inhibitor use and costs. Results: In this study, 113,560 prescriptions were dispensed in 89 cities, mostly to women (57.6%) with a mean age of 54.4 ± 18.7 yrs; the drugs were omeprazole (n= 111,294; 97.8%), esomeprazole (n= 1,378; 1.2%), lansoprazole (n= 524; 0.4%), pantoprazole and rabeprazole. The indication for 87,349 of the formulas (76.9%) was justified and statistically associated with the use of NSAIDs, antithrombotics, corticosteroids, anti-ulcer, antibiotics and prokinetics. No justification was found for 26,211 (23.1%) of the prescriptions, which were associated with antidiabetics, antihypertensives, hypolipidemics and others (p <0.001). The annual justified cost was estimated to be US$ 1,654,701 and the unjustified cost was estimated to be U.S. $ 2,202,590, as calculated using the minimum reference prices. Discussion: Each month, the Colombian health system is overloaded by unjustified costs that include payments for non-approved indications of proton pump inhibitors and for drugs outside the list of essential medications.This issue is contributing to rising costs of healthcare in Colombia.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Prescribing patterns and economic costs of proton pump inhibitors in Colombia

et al. 2013

View full text Add to dashboard Cite

show abstract

Detection and analysis of drug�drug interactions among hospitalized cardiac patients in the Mohammed V Military Teaching Hospital in Morocco

Fettah¹,

Moutaouakkil²,

Sefrioui³

et al. 2018

Pan Afr Med J

View full text Add to dashboard Cite

IntroductionDrug-drug interactions (DDIs) are defined as two or more drugs interacting in such a manner that the effectiveness or toxicity of one or more drugs is altered. Patients with cardiovascular disorders are at higher risk for DDIs because of the types and number of drugs they receive. The aim of the present study was to assess the prevalence of DDIs in patients admitted to the cardiology department of a hospital in Morocco.MethodsA prospective observational study from June 2016 to September 2016 was carried out in the cardiology department of a hospital in Morocco. Those patients who were taking at least two drugs and had a hospital stay of at least 48 hours were included in the study. The medications of the patients were analysed for possible interactions. All the prescriptions of the study population were screened for drug-drug interactions using a computerized DDI database system (Theriaque®).ResultsDuring the study period, 138 patients were included; 360 interactions were detected among 94 patients, with an average number of drugs taken of 5.2. The prevalence of DDIs was estimated at 68.11%, the most common of which concerned Kardegic/Plavix (12.22%), Kardegic/Heparin (8.33%), and Lasilix/Spironolactone (5.83%). Among the 726 prescribed drugs, (372 [51.24%]) were drugs of the cardiovascular system, followed by blood and hematopoietic organ drugs (288 [39.67%]) according to the Anatomical Therapeutic Chemical Classification codes. These interactions were categorized on the basis of level of severity: interactions with major severity accounted for 11.11% (40) of the total DDIs while those with moderate and minor severity accounted for 37.22% (134) and 51.66% (186), respectively.ConclusionThis study reports the prevalence of DDIs in patients admitted to the cardiology department of a hospital in Morocco. This study shows that DDIs are frequent among hospitalized cardiac patients and highlights the need to screen prescriptions of cardiovascular patients for possible DDIs, as this helps in their detection and prevention.Pan African Medical Journal – ISSN: 1937- 8688 (www.panafrican-med-journal.com)Published in partnership with the African Field Epidemiology Network (AFENET). (www.afenet.net)Pan African Medical Journal – ISSN: 1937- 8688 (www.panafrican-med-journal.com)Published in partnership with the African Field Epidemiology Network (AFENET). (www.afenet.net)

show abstract

Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?

Noor

Ismail

Ali

2019

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background Pneumonia patients are usually hospitalized due to severe nature of the disease or for the management of comorbid illnesses or associated symptoms. Such patients are prescribed with multiple medications which increase the likelihood of potential drug-drug interactions (pDDIs). Therefore, in this study the prevalence, levels (severity and documentation), predictors (risk factors), and clinical relevance of pDDIs among inpatients diagnosed with pneumonia have been investigated. Methods Clinical records of 431 hospitalized patients with pneumonia were checked for pDDIs using drug interactions screening software (Micromedex-DrugReax). Odds-ratios for predictors were calculated using logistic regression analysis. Clinical relevance of pDDIs was assessed by evaluation of patients’ clinical profiles for potential adverse outcomes of the most frequent pDDIs. Abnormal patients’ signs/symptoms and laboratory investigations indicating adverse outcomes of interactions were reported. Results Of total 431 profiles, pDDIs were reported in 73.1%. Almost half of the profiles were having major-pDDIs (53.8%). Total number of pDDIs were 1318, of which 606 were moderate- and 572 were major-pDDIs. Patient’s profiles identified with the most frequent interactions were presented with signs, symptoms, and abnormalities in labs indicating decrease therapeutic response, electrolyte abnormalities, hypoglycemia, bleeding, hepatotoxicity, and hypertension. These adverse events were more prevalent in patients taking higher doses of the interacting drugs as compared to lower doses. Logistic regression analysis revealed significant association for major-pDDIs with 6–10 prescribed medicines (OR = 26.1; p = 0.002), > 10 prescribed medicines (OR = 144; p < 0.001), and tuberculosis (OR = 8.2; p = 0.004). Conclusions PDDIs are highly prevalent in patients with pneumonia. Most frequent and clinically important pDDIs need particular attention. Polypharmacy and tuberculosis increase the risk of pDDIs. Identifying patients more at risk to pDDIs and careful monitoring of pertinent signs/symptoms and laboratory investigations are important measures to reduce pDDIs and their related adverse consequences.

show abstract

Drug-Drug Interactions in Patients From an Internal Medicine Service

Cited by 6 publications

References 13 publications

Prescribing patterns and economic costs of proton pump inhibitors in Colombia

Prescribing patterns and economic costs of proton pump inhibitors in Colombia

Detection and analysis of drug�drug interactions among hospitalized cardiac patients in the Mohammed V Military Teaching Hospital in Morocco

Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?

Contact Info

Product

Resources

About